EGFRmutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
Open Access
- 21 November 2012
- journal article
- review article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 66 (2), 79-89
- https://doi.org/10.1136/jclinpath-2012-201194
Abstract
Aims: Activating mutations in the gene encoding epidermal growth factor receptor (EGFR) can confer sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib in patients with advanced non-small-cell lung cancer. Testing for mutations inEGFRis therefore an important step in the treatment-decision pathway. We reviewed reported methods forEGFRmutation testing in patients with lung cancer, initially focusing on studies involving standard tumour tissue samples. We also evaluated data on the use of cytology samples in order to determine their suitability forEGFRmutation analysis.Methods: We searched the MEDLINE database for studies reporting onEGFRmutation testing methods in patients with lung cancer.Results: Various methods have been investigated as potential alternatives to the historical standard forEGFRmutation testing, direct DNA sequencing. Many of these are targeted methods that specifically detect the most commonEGFRmutations. The development of targeted mutation testing methods and commercially available test kits has enabled sensitive, rapid and robust analysis of clinical samples. The use of screening methods, subsequent to sample micro dissection, has also ensured that identification of more rare, uncommon mutations is now feasible. Cytology samples including fine needle aspirate and pleural effusion can be used successfully to determineEGFRmutation status provided that sensitive testing methods are employed.Conclusions: Several different testing methods offer a more sensitive alternative to direct sequencing for the detection of commonEGFRmutations. Evidence published to date suggests cytology samples are viable alternatives for mutation testing when tumour tissue samples are not available.Keywords
This publication has 94 references indexed in Scilit:
- EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinomaCellular Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung CancerThe Journal of Molecular Diagnostics, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineEMBO Molecular Medicine, 2010
- Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancersBritish Journal of Cancer, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinibBritish Journal of Cancer, 2006
- Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancerBritish Journal of Cancer, 2006